
Jian Zhang, MD, details the rationale of evaluating SIM0270 plus everolimus in patients with ER-positive/HER2-negative advanced breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Jian Zhang, MD, is a professor at Fudan University Shanghai Cancer Center in China.

Jian Zhang, MD, details the rationale of evaluating SIM0270 plus everolimus in patients with ER-positive/HER2-negative advanced breast cancer.

Jian Zhang, MD, discusses SIM0270, a brain-penetrant oral SERD, in combination with everolimus, in ER-positive, HER2-negative advanced breast cancer.

Published: January 21st 2025 | Updated: